Preparation of protein loaded poly(d,l-lactide-co-glycolide) microparticles for the antigen delivery to dendritic cells using a static micromixer

2006 ◽  
Vol 62 (3) ◽  
pp. 247-253 ◽  
Author(s):  
C WISCHKE ◽  
D LORENZEN ◽  
J ZIMMERMANN ◽  
H BORCHERT
Blood ◽  
2009 ◽  
Vol 114 (24) ◽  
pp. 4989-4997 ◽  
Author(s):  
Marc Bajénoff ◽  
Ronald N. Germain

Abstract Afferent lymph is transported throughout lymph nodes (LNs) by the conduit system. Whereas this conduit network is dense in the T-cell zone, it is sparse in B-cell follicles. In this study, we show that this differential organization emerges during lymph node development. Neonatal LNs lack B follicles, but have a developed T-cell zone and a dense conduit network. As new T and B cells enter the developing LN, the conduit network density is maintained in the T, but not the B zone, leading to a profound remodeling of the follicular network that nevertheless maintains its connectivity. In adults, the residual follicular conduits transport soluble antigen to deep regions, where follicular dendritic cells are abundant and appear to replace the fibroblastic reticular cells that enwrap conduits in the T zone. This strategic location correlates with the capacity of the follicular dendritic cells to capture antigen even in the absence of antigen-specific antibodies. Together, these results describe how the stromal organization of the T and B regions of LNs diverges during development, giving rise to distinct antigen transport and delivery modes in the 2 compartments.


2015 ◽  
Vol 82 (6) ◽  
pp. 498-505 ◽  
Author(s):  
L. H. Pugholm ◽  
K. Varming ◽  
R. Agger

2002 ◽  
Vol 109 (11) ◽  
pp. 1463-1470 ◽  
Author(s):  
Helen Y. Wang ◽  
Tihui Fu ◽  
Gang Wang ◽  
Gang Zeng ◽  
Donna M. Perry-Lalley ◽  
...  

Cancers ◽  
2019 ◽  
Vol 11 (5) ◽  
pp. 670 ◽  
Author(s):  
Aleksandar Murgaski ◽  
Pauline M. R. Bardet ◽  
Sana M. Arnouk ◽  
Emile J. Clappaert ◽  
Damya Laoui

Recent advances in cancer immunotherapy have mainly focused on re-activating T-cell responses against cancer cells. However, both priming and activation of effector T-cell responses against cancer-specific antigens require cross-talk with dendritic cells (DCs), which are responsible for the capturing, processing and presentation of tumour-(neo)antigens to T cells. DCs consequently constitute an essential target in efforts to generate therapeutic immunity against cancer. This review will discuss recent research that is unlocking the cancer-fighting potential of tumour-infiltrating DCs. First, the complexity of DCs in the tumour microenvironment regarding the different subsets and the difficulty of translating mouse data into equivalent human data will be briefly touched upon. Mainly, possible solutions to problems currently faced in DC-based cancer treatments will be discussed, including their infiltration into tumours, activation strategies, and antigen delivery methods. In this way, we hope to put together a broad picture of potential synergistic therapies that could be implemented to harness the full capacity of tumour-infiltrating DCs to stimulate anti-tumour immune responses in patients.


Blood ◽  
2012 ◽  
Vol 120 (10) ◽  
pp. 2011-2020 ◽  
Author(s):  
Bithi Chatterjee ◽  
Anna Smed-Sörensen ◽  
Lillian Cohn ◽  
Cécile Chalouni ◽  
Richard Vandlen ◽  
...  

Abstract Dendritic cells (DCs) can capture extracellular antigens and load resultant peptides on to MHC class I molecules, a process termed cross presentation. The mechanisms of cross presentation remain incompletely understood, particularly in primary human DCs. One unknown is the extent to which antigen delivery to distinct endocytic compartments determines cross presentation efficiency, possibly by influencing antigen egress to the cytosol. We addressed the problem directly and quantitatively by comparing the cross presentation of identical antigens conjugated with antibodies against different DC receptors that are targeted to early or late endosomes at distinct efficiencies. In human BDCA1+ and monocyte-derived DCs, CD40 and mannose receptor targeted antibody conjugates to early endosomes, whereas DEC205 targeted antigen primarily to late compartments. Surprisingly, the receptor least efficient at internalization, CD40, was the most efficient at cross presentation. This did not reflect DC activation by CD40, but rather its relatively poor uptake or intra-endosomal degradation compared with mannose receptor or DEC205. Thus, although both early and late endosomes appear to support cross presentation in human DCs, internalization efficiency, especially to late compartments, may be a negative predictor of activity when selecting receptors for vaccine development.


2009 ◽  
Vol 121 (45) ◽  
pp. 8637-8641 ◽  
Author(s):  
Stefaan De Koker ◽  
Bruno G. De Geest ◽  
Satwinder K. Singh ◽  
Riet De Rycke ◽  
Thomas Naessens ◽  
...  

2014 ◽  
Vol 192 (12) ◽  
pp. 5830-5838 ◽  
Author(s):  
Kirsten Neubert ◽  
Christian H. K. Lehmann ◽  
Lukas Heger ◽  
Anna Baranska ◽  
Anna Maria Staedtler ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document